Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tonabacase (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors iNtRON Biotechnology

    • Most Recent Events

    • 10 Jan 2022 Results evaluating the safety and pharmacokinetics following administration of single and multiple doses of the anti-staphylococcal lysin in healthy adult subjects published in the Antimicrobial Agents and Chemotherapy
    • 27 Mar 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 18 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top